The groundbreaking preprint study conducted by Truveta, a prominent healthcare data company, sheds light on the comparative effectiveness of Eli Lilly’s Mounjaro (tirzepatide) and Novo Nordisk’s Ozempic (semaglutide) in aiding weight loss among patients with Type 2 diabetes. The comprehensive research, which analyzed electronic health records (EHRs) from 41,223 overweight or obese patients, stands as the first real-world comparative effectiveness study between these two medications.
To ensure the robustness of the findings, the cohort was meticulously selected, focusing on patients with available weight data and those who had not previously received a glucagon-like peptide-1 receptor agonist before May 2022. The study discovered that despite approximately 77% of the patients being on Ozempic, those who opted for Mounjaro exhibited significantly higher probabilities of achieving 5%, 10%, and 15% weight loss. Additionally, Mounjaro users experienced more substantial reductions in weight at 3, 6, and 12 months compared to their Ozempic counterparts.
The research’s magnitude is amplified by the involvement of Truveta, a healthcare data company renowned for collecting EHR information from over 30 systems. This collaboration underscores the reliability and real-world applicability of the study’s results. The study, published as a preprint, provides valuable insights into the practical implications of Mounjaro and Ozempic in managing weight among patients with Type 2 diabetes.
Tyler Gluckman, MD, a study co-author and the medical director of Providence St. Joseph Health’s Center for Cardiovascular Analytics, Research, and Data Science, emphasized the significance of the study’s findings in a Nov. 27 news release. Dr. Gluckman highlighted that assessing the real-world effects of semaglutide (Ozempic) and tirzepatide (Mounjaro) on weight loss offers a glimpse into what can be expected with the recently approved obesity drug tirzepatide, known by the brand name Zepbound. This insight into the comparative effectiveness of these medications provides valuable information for healthcare professionals and patients alike, guiding decisions in the management of obesity and associated conditions.
In summary, this pioneering study by Truveta not only establishes Mounjaro’s superiority over Ozempic in promoting weight loss among patients with Type 2 diabetes but also serves as a benchmark for future research, especially in the context of emerging obesity drugs like tirzepatide (Zepbound) and their potential comparison with existing medications such as semaglutide (Wegovy).